top of page
    • Sep 21

Lars Lannfelt, inventor of the approved (in the U.S. and elsewhere) Alzheimer's medicine Leqembi, describes how the drug works and shares his understanding of Alzheimer's disease

Professor Lannfelt recounts the history of researching amyloid beta and explains why he thinks it is vital to target amyloid beta protofibrils to have an impact on the disease. Plus, the future of treating Alzheimer's earlier and getting more of the medicine into the brain, both of which BioArctic is currently working on.




Comments

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

Visit NYSE

bottom of page